Epratuzumab is an emerging monoclonal specific to CD22, an surface protein present largely on Immune cells . Its process of effect consists of blocking CD22-mediated signaling , as a result reducing Immune cell growth and inducing cell death . Clinical results indicate promise for a management of inflammatory conditions, especially cancers and trea